Swamy Kumara, Sathiya Narayanan V K, Basu Sumeet, Maiya Vikram, Achari Rimpa, Deshpande Shrikant, Bhangle Janhavi, Gupta Kamlesh Kumar, Babu Nirmal, Pawar Surendra, Atre Ashish, Balachandra Kashyapi, Koppiker C B
Department of Radiation Oncology, Ruby Hall Cancer Center, Ruby Hall Clinic, 40, Sassoon Road, Pune-411 001, Maharashtra, India.
J Cancer Res Ther. 2009 Oct-Dec;5(4):277-83. doi: 10.4103/0973-1482.59909.
Increasing incidence and significant stage migration from distant metastases to a localized disease, due to screening application of PSA, is taking place in carcinoma prostate. Also, role of radiotherapy is increasing in carcinoma prostate due to rapid strides in technology.
The present retrospective study, evaluates escalating the dose in the treatment of localized carcinoma prostate using integration of multiple advanced techniques.
The settings designed are: a) use of gold seed internal fiducial markers: b) clinical application of emerging Megavoltage Cone Beam Computed Tomography (MVCBCT) technology for Image Guided Radiotherapy (IGRT); c) Intensity Modulated Radiotherapy (IMRT); d) adopting biochemical method for follow-up.
Twelve consecutive, biopsy proven localized cancer of prostate patients, treated with dose escalation IMRT & IGRT protocol between August 2006 and January 2008, were analyzed. Gold seed markers in prostate were used for daily localization with MVCBCT or Electronic Portal Imaging (EPI). All patients underwent clinical and biochemical follow-up. STATISTICAL ANALYSIS & RESULTS: Planned dose of 7740 cGy was delivered in 10 out of 12 patients (83%). While one patient had migration of maximum of 3 mm, two others had 1 mm migration of one seed during course of treatment. One patient (8%) developed Grade II proctitis at 12th month. During the mean follow-up duration of 12.2 months, 92% (11/12) had biochemical control within 3 months of treatment.
IGRT technique using MVCBCT for implanted fiducial gold seed localization was feasible for IMRT dose escalation in carcinoma prostate with excellent results.
由于前列腺特异性抗原(PSA)筛查的应用,前列腺癌的发病率不断上升,且疾病分期从远处转移显著向局限性疾病转变。此外,由于技术的快速发展,放射治疗在前列腺癌中的作用也在增加。
本回顾性研究评估使用多种先进技术相结合来提高局限性前列腺癌治疗剂量的效果。
设计的设置包括:a)使用金种子内部基准标记物;b)将新兴的兆伏级锥形束计算机断层扫描(MVCBCT)技术临床应用于图像引导放射治疗(IGRT);c)调强放射治疗(IMRT);d)采用生化方法进行随访。
分析了2006年8月至2008年1月期间连续12例经活检证实为局限性前列腺癌的患者,这些患者接受了剂量递增的IMRT和IGRT方案治疗。前列腺中的金种子标记物用于通过MVCBCT或电子射野影像(EPI)进行每日定位。所有患者均接受临床和生化随访。
12例患者中有10例(83%)接受了计划剂量7740厘戈瑞的治疗。1例患者在治疗过程中最大移位3毫米,另外2例患者有1枚种子移位1毫米。1例患者(8%)在第12个月时出现了Ⅱ级直肠炎。在平均12.2个月的随访期间,92%(11/12)的患者在治疗后3个月内实现了生化控制。
使用MVCBCT对植入的基准金种子进行定位的IGRT技术在前列腺癌IMRT剂量递增中是可行的,且效果良好。